



University of Dundee and Corbin Therapeutics enter into collaboration agreement to discover novel ubiquitin-specific protease inhibitors

FOR IMMEDIATE RELEASE

Dundee, Scotland UK and Montreal, Québec, Canada, May 22, 2017 – University of Dundee, its Drug Discovery Unit (“DDU”), and Corbin Therapeutics (“Corbin”) are pleased to announce their collaboration agreement to screen and identify small molecules capable of efficiently inhibiting a well-conserved ubiquitin-specific protease, USP15.

Corbin focuses on a novel therapeutic approach to treat various inflammatory disorders via USP15 inhibition. Recently published in *Nature Immunology* [(2017) 18:54–63], this protease is central in the neuro-inflammation pathology and its inhibition might be key preventing and treating inflammatory-based diseases, such as multiple sclerosis.

DDU has expanded its drug discovery capabilities towards a unique collaborative model, which maximizes the translation of life sciences research into therapeutic applications. The DDU works with partners across a wide variety of disciplines, including high-throughput screening, DMPK, medicinal chemistry, bioinformatics and computational drug design.

Dr. Maxime Ranger, President and Chief Executive Officer of Corbin, commented, “We are very pleased to make this alliance with DDU, where both combine their complementary expertise into novel target validation and efforts to identify promising inhibitors of USP15.” Professor Paul Wyatt, Head of the DDU, added, “The DDU is committed to working collaboratively with partners, such as Corbin, to develop potential drug targets for diseases of unmet clinical need. We look forward to developing a productive partnership on this exciting target”

About Corbin Therapeutics

Corbin Therapeutics (www.corbinthera.com) is a Montreal-based biotechnology company, using a unique drug discovery platform to identify and develop novel USP15 inhibitors for treatment of various inflammation diseases, such as multiple sclerosis. This platform includes several *in-vitro* and *in-vivo* models for efficient drug screening and confirmation of potential lead candidates. Corbin is a spin-out company of AmorChem, a prominent investor in academic research in Quebec and Ontario (Canada). At its creation, all technology rights to the USP15 technology have been transferred from AmorChem to Corbin.

About DDU.

The Drug Discovery Unit (DDU) (www.drugdiscovery.dundee.ac.uk) is a fully integrated drug discovery operation based within a world class Life Sciences research environment. Its remit is to tackle both neglected diseases (trypanosomiasis, leishmaniasis and malaria) and early stage small molecule validation of novel targets & mechanisms across a range of potential therapeutic areas. The DDU works to Biotech style



philosophy and standards incorporating, dynamic, goal driven project management based on Target Product Profiles and Compound Selection Criteria. The project goals are therapeutic area dependent but range from quality leads demonstrating disease model proof of concept, through to pre-clinical candidates.

Contacts Corbin

Dr. Maxime Ranger
President and Chief Executive Officer
T : +1.514.825.9035
E : mranger@corbinthera.com

Dr. Philippe Gros
Chief Scientific Officer
T: +1.514.398.7291
E: pgros@corbinthera.com
Affiliated to McGill University

Contacts DDU

Professor Paul Wyatt FRSE
Head of the Drug Discovery Unit
College of Life Sciences, University of Dundee, Dundee
T: +44 (0) 1382 386231 ext. 86231
E: p.g.wyatt@dundee.ac.uk